Cross-protectivity of henipavirus soluble glycoprotein in an in vivo model of Nipah virus disease
This is first time the NiV and HeV soluble glycoproteins have been compared in the NiV-M hamster challenge model in the presence of Alhydrogel and AddaVax, providing evidence that glycoproteins from closely related henipavirus species can provide cross-protectivity against infection from alternate henipaviruses, supporting the potential of an effective pan-henipavirus vaccine for use in a frontline outbreak response.
Authors
- Susan Fotheringham (ORCID: https://orcid.org/0000-0001-5440-8747)
- Lucy Crossley
- Inés Ruedas‐Torres (ORCID: https://orcid.org/0000-0002-5851-1888)
- Emma Kennedy (ORCID: https://orcid.org/0000-0002-3632-6163)
- Dalan Bailey (ORCID: https://orcid.org/0000-0002-5640-2266)
- Nazia Thakur (ORCID: https://orcid.org/0000-0002-4450-5911)
- Francisco J. Salguero (ORCID: https://orcid.org/0000-0002-5315-3882)
- Stuart Dowall (ORCID: https://orcid.org/0000-0001-7378-8167)
- Linda Easterbrook
- Stephen Findlay‐Wilson (ORCID: https://orcid.org/0000-0002-6805-2574)
Institutions
- The Pirbright Institute (GB)
- University of Oxford (GB)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.3389/fimmu.2025.1517244
- Citations
- 3
- Primary Topic
- Virology and Viral Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- UK Research and Innovation